Trending...
- Spokane: Water Wise Wednesday Workshops Begin March 4
- Spokane: SPD Releases the Names of the Officers Involved in the OIS on Carlisle
- Spokane: Funding Available for Tourism and Cultural Investment Grant
STUART, Fla., April 19, 2024 ~ Stuart Therapeutics, Inc., a clinical-stage ophthalmic biopharmaceutical company, is making strides in the development of therapies for various eye disorders. The company's President and CEO, Eric Schlumpf, will be presenting their latest research results at two upcoming meetings in early May.
On Friday, May 3rd, Schlumpf will be speaking at the Dry Horizons Symposium, co-sponsored by Ora, Inc. His presentation will focus on Stuart Therapeutics' innovative dry eye disease program, which is currently in a Phase 3 trial. The following day, Saturday May 4th, he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and exudative retinal indications at the Ophthalmology Innovation Source (OIS) Retina Meeting.
Both of these meetings will take place at the Four Seasons Hotel in Seattle, Washington. This provides an opportunity for Stuart Therapeutics to showcase their groundbreaking research to a wide audience of industry professionals.
More on Washingtoner
In addition to Schlumpf's presentations, members of Stuart Therapeutics' R&D team have also co-authored a poster presentation that will be presented by researchers from the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 5-9, 2024. The poster presentation titled "Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation" focuses on work done at the University of Rochester using Stuart Therapeutics' proprietary collagen mimetic peptide platform. This research aims to understand its effectiveness in reversing scleral collagen disruption in the eye, which is believed to contribute to myopia.
The study authors include Aldo Tecse, Kaitlin Wozniak, James German, Alex McMullen, Mark Buckley, Robert Baratta, Eric Schlumpf, Brian J. Del Buono, Michael Telias and Susana Marcos. This collaboration between Stuart Therapeutics and the University of Rochester highlights the company's commitment to advancing the field of ophthalmology and finding new treatments for eye disorders.
Stuart Therapeutics' presence at these upcoming meetings demonstrates their dedication to innovation and their potential to make a significant impact in the field of ophthalmology. With their cutting-edge research and promising results, they are poised to become a leader in developing therapies for anterior segment, refractive, and posterior segment eye disorders.
On Friday, May 3rd, Schlumpf will be speaking at the Dry Horizons Symposium, co-sponsored by Ora, Inc. His presentation will focus on Stuart Therapeutics' innovative dry eye disease program, which is currently in a Phase 3 trial. The following day, Saturday May 4th, he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and exudative retinal indications at the Ophthalmology Innovation Source (OIS) Retina Meeting.
Both of these meetings will take place at the Four Seasons Hotel in Seattle, Washington. This provides an opportunity for Stuart Therapeutics to showcase their groundbreaking research to a wide audience of industry professionals.
More on Washingtoner
- The GUBERMAN Anomaly: Boeing's Alliance with ANSI–ANAB Exposed in Federal Contract 19AQMM18R0131
- Danholm Collection Launches Boutique Luxury Real Estate Brokerage in Central Florida
- Sellvia Market Expands Curated Store Portfolio for Dropshipping Sellers
- Food Journal Magazine Raises the Standard for Restaurant Reviews in Los Angeles
- StaffReady Expands Its Clinical Workforce Platform with ScheduleReady Compliance and Scheduling Suite
In addition to Schlumpf's presentations, members of Stuart Therapeutics' R&D team have also co-authored a poster presentation that will be presented by researchers from the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 5-9, 2024. The poster presentation titled "Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation" focuses on work done at the University of Rochester using Stuart Therapeutics' proprietary collagen mimetic peptide platform. This research aims to understand its effectiveness in reversing scleral collagen disruption in the eye, which is believed to contribute to myopia.
The study authors include Aldo Tecse, Kaitlin Wozniak, James German, Alex McMullen, Mark Buckley, Robert Baratta, Eric Schlumpf, Brian J. Del Buono, Michael Telias and Susana Marcos. This collaboration between Stuart Therapeutics and the University of Rochester highlights the company's commitment to advancing the field of ophthalmology and finding new treatments for eye disorders.
Stuart Therapeutics' presence at these upcoming meetings demonstrates their dedication to innovation and their potential to make a significant impact in the field of ophthalmology. With their cutting-edge research and promising results, they are poised to become a leader in developing therapies for anterior segment, refractive, and posterior segment eye disorders.
0 Comments
Latest on Washingtoner
- Jack and Sage Acquires Sustainable Apparel Brand Kastlfel, Expanding Premium Logo Wear Across National Parks and Ski Resorts
- The Media Should Protect the Public When It Comes to Boeing — But Does It?
- Cancun International Airport Prepares for Record Travel Surge Ahead of Spring Break, Summer, and the 2026 High Season
- $167 Billion Pharma R&D Market Largely Untapped by AI Creates Major Growth Runway for KALA Bios Data-Sovereign AI Strategy: N A S D A Q: KALA
- Lighthouse Tech Awards Recognize Top HR Technology Providers for 2026
- ADB Selects OneVizion to Advance Field Execution and Infrastructure Program Management
- Memelinked Social Media powered by cryptocurrency launching July 2026
- Seven-Year-Old Toronto Dancer Julianna Selivanov Wins Nine Medals at Quebec Championship and Reaches Finals at UK Dance Festival
- Independent Financial Agencies Upgrade City of Tacoma's Bond Ratings Amid Broader Economic Uncertainty
- City of Spokane Partners with North Hill Christian Church, Jewels Helping Hands to Open New Scattered Site Shelter
- Progressive Dental & The Closing Institute Partner with Zest Dental Solutions to Elevate Full-Arch Growth and Patient Outcomes
- Tacoma City Council Votes to Enter Negotiations with Hyun Kim for City Manager Role
- Tacoma: Registration Now Open for Grit City Connect Networking Event
- HiLine Homes Celebrates Grand Opening of Marysville Model Home with Ribbon-Cutting Ceremony
- Spokane: City Council Bans Use of Private Property for Detention Facilities
- Spring Surge in 55+ Communities: What Buyers and Sellers Need to Know in 2026
- Spokane: City Council Adopts "Immigration Enforcement Free Zones" Ordinance
- Spokane City Council Approves Prohibition of Kraton Sales
- Jason Caras Launches The Caras Institute Following Successful Exit from IT Authorities
- Tacoma: Mayor Anders Ibsen to Deliver First State of the City Address on March 4